PERSPECTIVE THERAPEUTICS INC
CATXNYSE AMERICANTrading Snapshot
- Day Range
- $550.02 – $554.71
- 52-Week Range
- $1.96 – $6.16
- Volume
- $2.61B
- Avg Volume
- $2.68B
- Shares Outstanding
- 114.0M
- Next Earnings
- Oct 28, 2026
Fundamentals Snapshot
- Annual Revenue
- $366,000
- Last Q Revenue
- $81,000
- P/E Ratio
- -1.7
- P/S Ratio
- 816.4x
- EPS (TTM)
- $-1.58
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +3386.9%
Why Investors Own CATX
- ✓High-growth profile — revenue up +1.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 66% gross margin and 10% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PERSPECTIVE THERAPEUTICS INC
CATX
StockOtter · stockotter.spaceAbout PERSPECTIVE THERAPEUTICS INC
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
PERSPECTIVE THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift CATX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
PERSPECTIVE THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.